Table II.
Analysis of semaphorin-3A and MMP-14 expression in the NSCLC group.
| Semaphorin-3A | MMP-14 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Variable | n | + (%) | − (%) | χ2 | P-value | + (%) | − (%) | χ2 | P-value |
| Pleural invasion | 5.6360 | 0.0176 | 5.3965 | 0.0202 | |||||
| No | 54 | 25 (46.30) | 29 (53.70) | 36 (66.67) | 18 (33.33) | ||||
| Yes | 40 | 9 (22.50) | 31 (77.50) | 35 (87.50) | 5 (12.50) | ||||
| Lymph node metastasis | 14.3348 | 0.0002 | 8.5288 | 0.0035 | |||||
| No | 37 | 22 (59.46) | 15 (40.54) | 22 (59.46) | 15 (40.54) | ||||
| Yes | 57 | 12 (21.05) | 45 (78.95) | 49 (85.96) | 8 (14.04) | ||||
| Number of metastatic lymph nodes | 7.2598 | 0.0071 | 7.5552 | 0.0060 | |||||
| <4 | 64 | 29 (45.31) | 35 (54.69) | 43 (67.19) | 21 (32.81) | ||||
| ≥4 | 30 | 5 (16.67) | 25 (83.33) | 28 (93.33) | 2 (6.67) | ||||
| Expression of PCNA, % | 23.4801 | <0.0001 | 5.7913 | 0.0161 | |||||
| <25 | 49 | 29 (59.18) | 20 (40.82) | 32 (65.31) | 17 (34.69) | ||||
| ≥25 | 45 | 5 (11.11) | 40 (88.89) | 39 (86.67) | 6 (13.33) | ||||
| Degree of differentiation | 8.7037 | 0.0032 | 9.4801 | 0.0021 | |||||
| Well and moderately | 56 | 27 (48.21) | 29 (51.79) | 36 (64.29) | 20 (35.71) | ||||
| Poorly | 38 | 7 (18.42) | 31 (81.58) | 35 (92.11) | 3 (7.89) | ||||
| Vascular invasion | 5.7928 | 0.0161 | 6.4769 | 0.0109 | |||||
| No | 66 | 29 (43.94) | 37 (56.06) | 45 (68.18) | 21 (31.82) | ||||
| Yes | 28 | 5 (17.86) | 23 (82.14) | 26 (92.86) | 2 (8.70) | ||||
| Maximum diameter of tumor, cm | 15.2753 | <0.0001 | 0.4966 | 0.4810 | |||||
| <5 | 44 | 25 (56.82) | 19 (43.18) | 31 (73.81) | 11 (26.19) | ||||
| ≥5 | 50 | 9 (18.00) | 41 (82.00) | 40 (80.00) | 10 (20.00) | ||||
Expression of semaphorin-3A and MMP-14 in patients presenting with different clinical characteristics. MMP, matrix metalloproteinase; NSCLC, non-small cell lung cancer; PCNA, proliferating cell nuclear antigen.